**Core Concept**
Methicillin-resistant S. aureus (MRSA) poses a significant challenge in healthcare settings due to its resistance to commonly used antibiotics, making treatment more difficult and expensive.

**Why the Correct Answer is Right**
The rigorous control measures for MRSA are primarily due to the limited treatment options available. Vancomycin is the most effective antibiotic against MRSA, but it is expensive and can have significant side effects, such as nephrotoxicity and ototoxicity. The high cost and potential toxicity of vancomycin make it a less desirable treatment option, necessitating strict infection control measures to prevent the spread of MRSA and minimize the need for prolonged treatment with this antibiotic.

**Why Each Wrong Option is Incorrect**
**Option A:** MRSA is not inherently more virulent than other staphylococci. While it can cause severe infections, its virulence is not significantly greater than that of antibiotic-susceptible S. aureus.

**Option C:** Toxic shock syndrome is a complication of S. aureus infection, but it is not a unique characteristic of MRSA. Both MRSA and antibiotic-susceptible S. aureus can cause toxic shock syndrome, making this option an incorrect reason for the rigorous control measures.

**Option D:** While MRSA can spread rapidly from patient to patient, this is not the primary reason for the stringent control measures. S. aureus, in general, is a highly contagious organism that can spread quickly in healthcare settings, but the specific concern with MRSA is its resistance to antibiotics, making treatment more challenging.

**Clinical Pearl / High-Yield Fact**
It's essential to note that the use of vancomycin-resistant S. aureus (VRSA) has been reported, making the situation even more critical. In such cases, treatment options are severely limited, and infection control measures become even more crucial to prevent the spread of VRSA.

**✓ Correct Answer: B. The alternative for treatment of MRSA is vancomycin, an expensive and potentially toxic antibiotic.**